Asieris Meditech Co., Ltd.

Asieris MediTech Co., Ltd., is a subsidiary of the China-based Jiangsu Yahong Meditech Co., Ltd., a specialty pharma company fully committed to research, development and commercialization of innovative new medical treatments through their own IP and in-licensing efforts. Its leading drug candidate, an oral drug for treating non-muscle invasive bladder cancer, is in a registrational clinical trial in China and Phase Ib trial in the US. *

	Start	2019-07-01 existent
	Group	Yahong Meditech (Group)
	Industry	pharmaceutical
	Person	Pan, Kevin (Yahong Meditech 201907 CEO of Asieris Meditech Co Ltd)

	Region	China_oo
	Country	China
	City	n. a.
		Address record changed: 2019-07-08

Basic data	Employees	n. a.

		* Document for »About Section«: Photocure ASA. (7/1/19). "Press Release: Photocure and Asieris Enter into a Global Licensing Deal for Cevira with up to USD 250 Million in Milestones and Double-digit Royalties". Oslo.

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Yahong Meditech (Group)

[1] Photocure ASA. (7/1/19). "Press Release: Photocure and Asieris Enter into a Global Licensing Deal for Cevira with up to USD 250 Million in Milestones and Double-digit Royalties". Oslo....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]